Diana Gallagher, MD, on the New Phase 2 FUSION Study of the BTK Inhibitor BIIB091 on NeuroVoices.

Published Date: 19 Oct 2023

Diana Gallagher, MD, discusses the new phase 2 FUSION study of the BTK inhibitor BIIB091 on NeuroVoices.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot